Cargando…

Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls

Clostridioides difficile infection (CDI) is one of the leading causes of hospital-acquired infection attributing to substantial morbidity, mortality, and healthcare cost. Recurrent CDI (rCDI) is common and occurs after effective treatment of first episode. Treatment of rCDI is based on accurate diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandhu, Avnish, Chopra, Teena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Clostridioides difficile Infection: Approaching a Difficult Menace
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725027/ https://www.ncbi.nlm.nih.gov/pubmed/34992678 http://dx.doi.org/10.1177/17562848211053105

Ejemplares similares

Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease
por: van Lingen, Emilie (E.), et al.
Publicado: (2023)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection
por: Seekatz, Anna Maria, et al.
Publicado: (2022)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
por: Mullish, Benjamin H., et al.
Publicado: (2021)

Invisible steps for a global endemy: molecular strategies adopted by Clostridioides difficile
por: Fettucciari, Katia, et al.
Publicado: (2021)

Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study
por: Saha, Srishti, et al.
Publicado: (2023)

Defining the black box: a narrative review of factors associated with adverse outcomes from severe Clostridioides difficile infection
por: Ressler, Adam, et al.
Publicado: (2021)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface
por: Sehgal, Kanika, et al.
Publicado: (2021)

Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review
por: Gupta, Akshita, et al.
Publicado: (2021)

Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
por: Hawes, Armani Minasian, et al.
Publicado: (2021)

A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores
por: Alabdali, Yasir Adil Jabbar, et al.
Publicado: (2021)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Clostridioides difficile Is Not Difficult to Predict in Hospital Settings
por: Alexander, Kinta, et al.
Publicado: (2021)

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection
por: McGovern, Barbara, et al.
Publicado: (2021)

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Evaluation of the genomic epidemiology and transmission of Clostridioides difficile infection across a community
por: Tesini, Brenda, et al.
Publicado: (2022)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection
por: Ray, Michael, et al.
Publicado: (2023)

Did Clostridioides difficile Testing and Infection Rates Change During the COVID-19 Pandemic?
por: Hawes, Armani, et al.
Publicado: (2021)

Prospective audit and feedback of Clostridioides difficile PCR at the time of ordering increases appropriateness of testing
por: Tassone, Daniel, et al.
Publicado: (2022)

Characteristics of antibiotic exposures for surgical procedures prior to Clostridioides difficile diagnosis—Minnesota, 2018
por: D’Heilly, Paige, et al.
Publicado: (2022)

Impact of Two-Step Testing Algorithm on Reducing Hospital-Onset Clostridioides difficile Infections
por: Navalkele, Bhagyashri, et al.
Publicado: (2021)

Impact of early identification of patients meeting testing criteria for Clostridioides difficile on standard infection ratios
por: Krier, Brad, et al.
Publicado: (2023)

Immunological mechanisms of fecal microbiota transplantation in recurrent Clostridioides difficile infection
por: Soveral, Lucas F, et al.
Publicado: (2022)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291
por: Buckley, Anthony M., et al.
Publicado: (2011)

Effects of a hard stop for C. difficile testing: Provider uptake and patient outcomes
por: Doughman, Danielle, et al.
Publicado: (2023)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Impact of exposure to potentially contaminated hospital beds on risk of hospital-onset C. difficile infection
por: Witt, Lucy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_blr7qf2f87iarl0k76rk7ts3rq